Short answer
AGIOS PHARMACEUTICALS, INC. (AGIO) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Press release covers Agios Pharmaceuticals’ quarter ended September 30, 2026.
AGIOS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers Agios Pharmaceuticals’ quarter ended September 30, 2026
- Results and business highlights are detailed in Exhibit 99.1
- Investors should review the exhibit for financial performance and operating updates
Item EX-99.1 · Exhibit EX-99.1
- Q3 product revenue $55.4M, more than four times $12.9M, signaling rapid commercial ramp for mitapivat
- U.S. revenue $48.7M and ex-U.S. revenue $6.6M, supported by AQVESME thalassemia launch and European expansion
- AQVESME reached 619 completed prescriptions plus 48 forms in process, with approximately 75% patient persistence at six months
- Sickle cell PDUFA date moved to February 1, 2027, delaying the largest potential indication and introducing REMS-related uncertainty
- Cash and investments $907.0M, while Q3 net loss narrowed to $65.0M; management targets non-GAAP profitability in 2028
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AGIOS PHARMACEUTICALS, INC. 8-K filings
Get the next AGIO 8-K as it lands
Follow AGIO for push alerts, or ask the research agent what this filing means.